Ovid Therapeutics
OVID
60 hedge funds and large institutions have $99.8M invested in Ovid Therapeutics in 2023 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 18 increasing their positions, 14 reducing their positions, and 7 closing their positions.
600% more call options, than puts
Call options by funds: $28K | Put options by funds: $4K
39% more capital invested
Capital invested by funds: $71.7M → $99.8M (+$28.1M)
29% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 14
0.14% more ownership
Funds ownership: 54.72% → 54.85% (+0.14%)
0% more funds holding
Funds holding: 60 → 60 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MAP
Madison Avenue Partners
New York
|
+$909K |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$410K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$360K |
| 4 |
Millennium Management
New York
|
+$311K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$254K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OMC
Oasis Management Company
Grand Cayman,
Cayman Islands
|
-$502K |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$410K |
| 3 |
D.E. Shaw & Co
New York
|
-$396K |
| 4 |
TA
TLS Advisors
Miami,
Florida
|
-$261K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$242K |
OVID Hedge Fund Activity: Q1 2023 in Review
60 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q1 2023, worth a combined $99.8M — up 39% from $71.7M a quarter earlier.
Fund positioning in OVID was balanced in Q1 2023: 7 funds opened new positions, 7 closed out, 18 added to existing stakes and 14 trimmed.
The largest buyer was Madison Avenue Partners, adding an estimated $909K. The largest seller was Oasis Management Company, exiting entirely with an estimated $502K sold.
- 60 institutional investors held Ovid Therapeutics (OVID) as of Q1 2023, unchanged from Q4 2022.
- Funds reported $99.8M of Ovid Therapeutics stock for Q1 2023, up 39% quarter-over-quarter.
- 7 funds opened new Ovid Therapeutics positions in Q1 2023 and 7 closed out, a net change of 0 holders.
- The largest Ovid Therapeutics buyer in Q1 2023 was Madison Avenue Partners, an estimated $909K added.
- The largest Ovid Therapeutics seller in Q1 2023 was Oasis Management Company, an estimated $502K sold.
Based on aggregated 13F filings for Q1 2023.